# US 2024/0197770 A1 · Compositions and methods for treating elastic fiber breakdown

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197770 A1
- Document ID: US20240197770A1
- Status: Published application
- Kind: A1
- Application number: 18/225,405
- Filed: 2023-07-24
- Published: 2024-06-20
- Earliest claimed: 2018-04-12
- Assignees: MatRx Therapeutics Corporation
- Applicants: MatRx Therapeutics Corporation
- Inventors: Jerome O. Cantor; Gerard M. Turino
- Web page: https://patentgrep.com/patent/US20240197770A1

## CPC

- A61K 31/728: Hyaluronic acid
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to pharmaceutical compositions capable of regulating elastic fiber. The disclosure further relates to methods of treating elastic fiber-related disorders, such as COPD, by inhalation of low-molecular weight hyaluronic acid.

## Claims

### Claim 1

A pharmaceutical composition comprising:
hyaluronic acid, or a pharmaceutically acceptable salt thereof, wherein the hyaluronic acid has a weight average molecular weight (Mw) of about 50 to about 1000 kDa; and
a pharmaceutically acceptable excipient.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the hyaluronic acid has a weight average molecular weight (Mw) of about 150 kDa.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, in a form suitable for inhalation.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, in a form suitable for nasal, intrapulmomary, intratracheal, intrabronchial, or intra-alveolar administration.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, in a form suitable for intra-alveolar administration.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, in a form suitable for administration through a dry powder inhaler.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, in a form suitable for administration through a liquid spray device.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the liquid spray device is an aerosol device.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the aerosol device is a nebulizer or electrohydrodynamic aerosol device.

### Claim 10 (depends on 1)

An inhaler comprising the pharmaceutical composition of claim 1.

### Claim 11 (depends on 10)

The inhaler of claim 10, configured to deliver droplets with a size of about 2 μm to about 3 μm.

### Claim 12

A method for treating an elastic fiber-related disorder in a subject, comprising administering to the subject hyaluronic acid, or a pharmaceutically acceptable salt thereof, wherein the hyaluronic acid has a weight average molecular weight (Mw) of about 50 to about 1000 kDa.

### Claim 13 (depends on 12)

The method of claim 12, wherein the hyaluronic acid has a weight average molecular weight (Mw) of about 150 kDa.

### Claim 14 (depends on 12)

The method of claim 12, comprising administering the hyaluronic acid via inhalation.

### Claim 15 (depends on 12)

The method of claim 12, comprising administering the hyaluronic acid to the paranasal sinuses, the pulmonary system, the trachea, the bronchia, or the alveoli.

### Claim 16 (depends on 12)

The method of claim 12, wherein the elastic fiber-related disorder is cutis laxa, Williams syndrome, alpha-1 antitrypsin deficiency, emphysema, Chronic Obstructive Pulmonary Disease (COPD), liver disease, Buschke-Ollendorff syndrome, Menkes disease, pseudoxanthoma elasticum, Marfan's syndrome, Hurler disease, hypertension or a congenital heart defect.

### Claim 17 (depends on 16)

The method of claim 16, wherein the elastic fiber-related disorder is COPD.
